复发性卵巢癌应用培美曲塞联合洛铂治疗的临床效果  

Clinical Effect of Pemetrexed Combined with Luoplatin on Recurrent Ovarian Cancer

作　　者：夏海清 米婷婷[1] 任红娟[1] XIA Haiqing;MI Tingting;REN Hongjuan(Nanyang Central Hospital,Nanyang,473000)

机构地区：[1]河南省南阳市中心医院,473000

出　　处：《实用癌症杂志》2021年第6期996-999,共4页The Practical Journal of Cancer

基　　金：河南省医学科技攻关计划项目(编号:2018062115)。

摘　　要：目的探讨培美曲塞联合洛铂治疗复发性卵巢癌的临床效果。方法选取复发性卵巢癌患者64例,采用随机数字表法,将患者随机分为试验组(n=31)和对照组(n=33)。试验组给予培美曲塞联合洛铂治疗,对照组给予吉西他滨联合洛铂治疗。观察2组近期疗效,糖类抗原125(CA125)、可溶性白细胞介素2受体(SIL-2R)和人附睾蛋白4(HE4)水平变化,不良反应等。结果试验组和对照组近期总有效率分别为32.26%和30.30%,无统计学差异(P>0.05)。试验组治疗后CA125、SIL-2R和HE4水平分别为(110.46±42.13)IU/ml、(201.47±94.55)ng/ml和(70.22±21.15)pmol/l,明显低于对照组(P<0.05)。试验组治疗后卡氏功能状态评分(KPS)评分为(88.16±6.84)分,明显高于对照组(P<0.05)。试验组3~4级血小板和白细胞下降发生率分别为22.58%和19.35%,明显低于对照组(P<0.05)。试验组中位无进展生存期(PFS)和总生存时间(OS)分别为6个月和11个月,明显长于对照组(P>0.05)。结论复发性卵巢癌应用培美曲塞联合洛铂治疗有较好的临床效果,不良反应较轻,在二线治疗中可推广使用。Objective To investigate the clinical effect of pemetrexed combined with looplatin in the treatment of recurrent ovarian cancer.Methods 64 patients with recurrent ovarian cancer were selected,Using random numbers,Patients were randomly divided into trial group(n=31)and the control group(n=33).The experimental group was treated with pemetrexed and loblatin,The control group was treated with gemcitabine and loblatin,To observe the short-term effects of the 2 groups,The changes of carbohydrate antigen 125(CA125),soluble interleukin 2 receptor(SIL-2R)and human epididymis protein 4(HE4)levels,Adverse reactions,etc.Results The total effective rates of the experimental group and the control group were 32.26%and 30.30%,respectively,and there was no statistical difference(P>0.05).The CA125、SIL-2R and HE4 levels in the experimental group were(110.46±42.13)IU/ml、(201.47±94.55)ng/ml and(70.22±21.15)respectively significantly lower than the control group(P<0.05).The Kjeldahl functional status score(KPS)was 88.16±6.84,significantly higher than the control group(P<0.05).Incidence of thrombocytopenia and leukopenia in grade 3 and 4 in the experimental group was 22.58%and 19.35%,respectively,which was significantly lower than the control group(P<0.05).The median progression-free survival(PFS)and total survival(OS)were 6 and 11 months,significantly longer than the control group(P>0.05).Conclusion The treatment of recurrent ovarian cancer with pemetrexed and loblatin is effective,with less adverse reactions,It can be popularized in second line therapy.

关 键 词：培美曲塞 洛铂 复发性卵巢癌 临床效果 

分 类 号：R737.31[医药卫生—肿瘤]